Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.
2.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr.

J Clin Oncol. 2004 May 1;22(9):1589-97.

PMID:
15117980
3.

Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients.

Wu YL, Sun Y, Zhou CC, Zhang L, Yu SY, Ma SL, Han LL, Zhang XQ, Orlando M.

Chin Med J (Engl). 2013;126(24):4624-8.

PMID:
24342300
4.

Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.

Karayama M, Inui N, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Suda T, Chida K.

Cancer Chemother Pharmacol. 2013 Aug;72(2):445-52. doi: 10.1007/s00280-013-2218-6.

PMID:
23807323
5.

Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.

Li R, Sun L, Wang J, Qian J, Wang Z, Jiao X.

Pulm Pharmacol Ther. 2012 Oct;25(5):364-70. doi: 10.1016/j.pupt.2012.06.008.

PMID:
22766314
6.

Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.

Sun Y, Wu YL, Zhou CC, Zhang L, Zhang L, Liu XY, Yu SY, Jiang GL, Li K, Qin SK, Ma SL, Han L, Quinlivan M, Orlando M, Zhang XQ.

Lung Cancer. 2013 Feb;79(2):143-50. doi: 10.1016/j.lungcan.2012.10.015.

PMID:
23182660
7.

Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.

Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA Jr, Kelly K.

J Clin Oncol. 2006 Sep 20;24(27):4405-11. Erratum in: J Clin Oncol. 2006 Dec 1;24(34):5477.

PMID:
16983108
8.

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.

Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Aug;68(2):415-22. doi: 10.1007/s00280-010-1508-5.

PMID:
21069335
9.

A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.

Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M, Orlando M.

J Thorac Oncol. 2011 Nov;6(11):1907-14. doi: 10.1097/JTO.0b013e318226b5fa.

PMID:
22005471
10.

Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis.

Di BS, Wei KP, Tian JH, Xiao XJ, Li Y, Zhang XH, Yu Q, Yang KH, Ge L, Huang WH, Zhang FW.

Asian Pac J Cancer Prev. 2014;15(8):3419-24. Review.

PMID:
24870732
11.

Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.

Chung FT, Lee KY, Fang YF, Shieh MH, Lin SM, Yu CT, Lo YL, Lin TY, Kuo CH, Feng PH, Ni YL, Kuo HP.

Chemotherapy. 2011;57(2):147-55. doi: 10.1159/000321037.

PMID:
21454972
12.
13.

Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.

Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, Crequit J, Bota S, Thomas P, Chouaid C; 0506 GFPC Team..

J Thorac Oncol. 2011 Jan;6(1):161-8. doi: 10.1097/JTO.0b013e318200f4c1.

PMID:
21150465
14.

Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.

Kim YH, Hirabayashi M, Kosaka S, Nikaidoh J, Yamamoto Y, Shimada M, Toyazaki T, Nagai H, Sakamori Y, Mishima M.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1445-51. doi: 10.1007/s00280-013-2142-9.

PMID:
23532206
15.

The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.

Kim YS, Sun JM, Ahn JS, Ahn MJ, Park K.

Lung Cancer. 2013 Aug;81(2):231-5. doi: 10.1016/j.lungcan.2013.04.011.

PMID:
23683535
16.

A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.

Dittrich C, Papai-Szekely Z, Vinolas N, Sederholm C, Hartmann JT, Behringer D, Kazeem G, Desaiah D, Leschinger MI, von Pawel J.

Eur J Cancer. 2014 Jun;50(9):1571-80. doi: 10.1016/j.ejca.2014.03.007.

PMID:
24703574
17.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP.

Lancet. 2009 Oct 24;374(9699):1432-40. doi: 10.1016/S0140-6736(09)61497-5.

PMID:
19767093
18.

Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):212-4.

PMID:
16400741
19.

Pemetrexed: a multitargeted antifolate.

Rollins KD, Lindley C.

Clin Ther. 2005 Sep;27(9):1343-82. Review.

PMID:
16291410
20.

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.

Scagliotti GV, Park K, Patil S, Rolski J, Goksel T, Martins R, Gans SJ, Visseren-Grul C, Peterson P.

Eur J Cancer. 2009 Sep;45(13):2298-303. doi: 10.1016/j.ejca.2009.04.033.

PMID:
19473833
Items per page

Supplemental Content

Support Center